Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 176   

Articles published

SNY 42.11 -0.01 (-0.02%)
price chart
Sanofi SA (ADR) and Diabetes: Things Are Not Working Out
Sanofi SA (NYSE:SNY) came into the spotlight after Food and Drug Administration (FDA) initiated a debate in association with its Diabetes Mellitus Type II combo drug LixiLan pointing out number of questions regarding the safety and clinical efficacy ...
Sanofi's LixiLan Faces Scrutiny From FDA  Bidness ETC
Sanofi SA (ADR) (SNY) Confirmed Confidentiality Agreement with Medivation Inc ...
As Medivation Inc (NASDAQ:MDVN) is headed towards a selloff, it is in talks with many parties who seek to buy the company. With Board of Directors consent, Medivation and Sanofi SA (ADR) (NYSE:SNY) have entered into confidentiality agreement.
Medivation Bidders Will Have To Price In Talazoparib; BMO Sees $68-$76 ...  Benzinga
Attention Seekers of Healthcare: AstraZeneca plc (ADR) (NYSE:AZN), Sanofi SA ...
AstraZeneca plc (ADR) (NYSE:AZN) shares went down -0.33% or -0.10 points to reach at $30.24 during the course of session. The stock traded in the range of $30.12 - $30.46 during its most recent trading session.
Sanofi SA (ADR) - DICE Deal To Replace Injectables With Oral Formulations
Sanofi SA (ADR) (NYSE:SNY) has announced it has signed an agreement with DiCE Molecules, for the research and development of novel molecules that can replace injectables with oral formulations, for certain diseases.
Sanofi and DICE on a Research Venture to Replace Injections with New Drugs  Bidness ETC
Sanofi SA (ADR) Scouts For New Cancer Treatments That Harness Immune Cells
Pharmaceutical giant Sanofi is partnering with two biotech companies -- Evotec AG in Hamburg, Germany, and Apeiron Biologics AG in Vienna, Austria - in its latest effort to develop a drug that harnesses the body's own immune system in the fight against ...
Sanofi SA (ADR) (NYSE:SNY) Looking To Acquire Medivation Inc (NASDAQ:MDVN) For ...
Sanofi SA (ADR) (NYSE:SNY) has made public its intention of acquiring Medivation Inc (NASDAQ:MDVN), having tabled a $9.3 billion takeover bid.
Sanofi Turns Hostile, Makes $9.3 Billion Bid for Medivation: A Smart Move?  Bidness ETC
Why Medivation Will Likely Reject Sanofi's $52.50/Share Buyout Offer  Benzinga
Pfizer Inc, Sanofi SA (ADR), Novartis AG (ADR): Who Will Acquire Medivation Inc?
The drugmakers are looking for M&A to expand their drug portfolios in order to make their drug pipeline more robust and competitive.
Medivation Inc Acquisition: Sanofi SA (ADR) Won't Take No for an Answer  Bidness ETC
If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi ...  Benzinga
Sanofi SA (ADR), Medivation Inc: Journey to Possible Hostile Takeover Begins
Sanofi SA (ADR) (NYSE:SNY) is all set to move forward with its proposal to oust Medivation board following the latter's refusal to accept its unsolicited $9.3 billion acquisition offer.
Sanofi ADRs Slip 3%; Says Bid For Medivation Offers Highest 'Transaction ...  Sonoran Weekly Review
Why Sanofi SA (ADR) (SNY) Is Trending on Wednesday
Sanofi SA (ADR) (NYSE:SNY) is preparing to oust all the board members of Medivation, Reuters reported on Wednesday, citing people familiar with the matter.
Is Sanofi SA (ADR) (SNY) Overvalued at Current Levels?  InvestCorrectly
Sanofi Seeks to Oust Medivation Board in Formidable Takeover Attempt  Bidness ETC
Inovio Pharmaceuticals Inc, Sanofi SA (ADR): Zika Virus Vaccine Failure is ...
According to GlaxoSmithKline plc (ADR) (NYSE:GSK), a vaccine minimally takes 10-15 years to get approved by the regulatory agencies such as Food and Drug Administration (FDA) and European Union (EU).